General Information of the Compound
Compound ID
CP0046809
Compound Name
(4-cyclobutyl-1,4-diazepan-1-yl)(6-(4-fluorophenoxy)pyridin-3-yl)methanone
    Show/Hide
Synonyms
Histamine H3 receptor antagonist (allergic rhinitis/alcoholism), Johnson & Johnson
JNJ-39220675
    Show/Hide
Structure
Formula
C21H24FN3O2
Molecular Weight
369.44
Canonical SMILES
Fc1ccc(Oc2ccc(cn2)C(=O)N2CCCN(CC2)C2CCC2)cc1
    Show/Hide
InChI
InChI=1S/C21H24FN3O2/c22-17-6-8-19(9-7-17)27-20-10-5-16(15-23-20)21(26)25-12-2-11-24(13-14-25)18-3-1-4-18/h5-10,15,18H,1-4,11-14H2
    Show/Hide
InChIKey
IQOWHZHNGJXGHG-UHFFFAOYSA-N
CAS
959740-39-7
Physicochemical Property
logP
3.7134
Rotatable Bonds
4
Heavy Atom Count
27
Polar Areas
45.67
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
4
Complexity
27

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 24771368
SID: 49692802
ChEMBL ID
CHEMBL1171754
DrugBank ID
DB12929
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01194, Histamine H3 receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000074 SK-N-MC Homo sapiens (Human)  2
1
Kd = 0.3802 nM
   TI
   LI
   LO
   TS
2
Ki = 1.4 nM
   TI
   LI
   LO
   TS
Protein ID: PT01173, Histamine H3 receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000074 SK-N-MC Homo sapiens (Human)  1
1
Kd = 3.548 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( JNJ-39220675 )
Drug Name JNJ-39220675
Company Johnson & Johnson Pharmaceutical Research & Development LLC
Indication
Alcohol dependence
Phase 2
Target(s)
Histamine H3 receptor (H3R)
Antagonist